个人简介：

Eiketsu Sho (Yongjie Zhuang), MD, PhD, has been working in the biotech industry and clinical medicine for over 30 years, with strong background in human and animal physiology and histopathology, especially in the area of preclinical in vivo pharmacology studies of cardiovascular disease, chronic inflammatory disease, liver disease, lung disease, kidney disease, metabolic disease and cancer. In the past 30 years, he has accrued extensive experience and techniques on human pathologic diagnosis, animal physiology and pathology, in vivo pharmacology and molecular pharmacology, also development of multiple animal disease models with skilled surgical techniques, especially microsurgical techniques.  Due to his excellent work, Dr. Sho became a key manager and director to move several compounds into clinical trials at KAI Pharmaceuticals. Since he was in a management and leadership position in a US biotech company over 10 years, he has also developed his knowledge, experience and skills on project supervision, management, and lab direction.  In early 2011, Dr. Sho joined KBI (a NHP CRO at Kunming, China) as the Chief Medical/Scientific Officer in charge of KBI science and technology development in the area of monkey preclinical disease models. In early 2014, he joined HD Biosciences at Shanghai, as an Executive Director in charge of in vivo pharmacology, pathology, toxicology, DMPK/PK, animal facility, etc.  In October, 2014, Dr. Sho started KCI Biotech, in Nanjing, later in Suzhou, China, as the President and CEO.  In January 2017, Dr. Sho started Jiangsu KMQ Biotech Inc.

公司简介：

凯斯艾生物科技（苏州）有限公司(KCI)是一家临床前药学服务外包公司，提供国际标准的一站式临床前药效学综合评价服务，致力于提供心脑血管，炎症，免疫性与代谢性疾病，肝脏和肾脏疾病领域的实验动物模型建立，包括啮齿类动物，兔犬和非人灵长类动物，，临床前药效学研究服务，药代/药效（PK/PD）研究服务，以及非GLP毒理和病理学评价服务。

高度专业化的科学知识水平是KCI生物医药专业领域服务的坚实基础，我们的实验动物模型可以达到药学实验要求的最高水平的精确性、可重复性和连贯性。

药理学模型：

专注于啮齿类和非人灵长类试验动物的心血管疾病，炎症，免疫性疾病，代谢疾病，肝脏疾病以及肾病等领域的疾病模型的开发与使用。

病理学：

大体器官病理学，组织器官病理学；肿瘤病理学，非肿瘤病理学，药学病理学以及毒理病理学。影像学公司自主安装了MRI，CT，X-光机。同时，公司拥有彩色B超等大型影像设备

公司官网：www.kcibiotech.com